However, a more remarkable feature recently revealed from our work, is the resistance of TRIB2-OE prostate cancer cells also to other second-generation anti-androgens that are frequently used in the clinic in addition to enzalutamide, such as apalutamide, darolutamide, and abiraterone (not shown). Here, TRIB2 is linked to prostate carcinoma.